Sagimet Biosciences (SGMT) Net Cash Flow (2022 - 2026)

Sagimet Biosciences' Net Cash Flow history runs 5 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 114.43% year-over-year to $1.6 million; the TTM figure through Mar 2026 stood at -$28.1 million (up 74.93% YoY), while the FY2025 annual figure was -$40.8 million, down 5922.97% from the prior year.
• Net Cash Flow for Q1 2026 stood at $1.6 million, down from $2.5 million in the prior quarter.
• The five-year high for Net Cash Flow was $101.6 million in Q1 2024, with the low at -$80.8 million in Q2 2024.
• The 5-year median for Net Cash Flow is -$1.6 million (2022), against an average of $2.0 million.
• The sharpest annual moves came in 2023 and 2024: Net Cash Flow soared 205766.67% in 2023, then slumped 1409.85% in 2024.
• Sagimet Biosciences' Net Cash Flow stood at -$2.1 million in 2022, then tumbled by 1188.75% to -$26.7 million in 2023, then jumped by 95.6% to -$1.2 million in 2024, then jumped by 315.08% to $2.5 million in 2025, then slumped by 36.44% to $1.6 million in 2026.
• Business Quant data shows SGMT's Net Cash Flow at $1.6 million in Q1 2026, $2.5 million in Q4 2025, and -$9.8 million in Q3 2025.